![](/img/cover-not-exists.png)
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Goldman, J.W., Garassino, M.C., Chen, Y., Reinmuth, N., Hotta, K., Poltoratskiy, A., Trukhin, D., Hochmair, M.J., ÃzgüroÄlu, M., Ji, J.H., Statsenko, G., Voitko, O., Conev, N.V., Bondarenko, I., SpVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.2328
Date:
September, 2020
File:
PDF, 88 KB
2020